Atlas Trials

Allogene Therapeutics

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Allogene Therapeutics

RecordFirmDate
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (NCT07085104)Allogene Therapeutics2025-11-13
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product (NCT06925685)Allogene Therapeutics2025-01-31
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (NCT06500273)Allogene Therapeutics2024-06-18
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (NCT05714345)Allogene Therapeutics2023-11-01
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (NCT05000450)Allogene Therapeutics2021-06-06
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (NCT04696731)Allogene Therapeutics2021-02-24
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (NCT04416984)Allogene Therapeutics2020-05-21
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (NCT04093596)Allogene Therapeutics2019-09-23
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (NCT03939026)Allogene Therapeutics2019-05-01

Track Allogene Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.